Obermeyer Wealth Partners Has $9.46 Million Stake in Novo Nordisk A/S (NYSE:NVO)

Obermeyer Wealth Partners grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 4.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 136,174 shares of the company's stock after acquiring an additional 6,070 shares during the period. Obermeyer Wealth Partners' holdings in Novo Nordisk A/S were worth $9,456,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. BIP Wealth LLC boosted its position in Novo Nordisk A/S by 3.9% during the fourth quarter. BIP Wealth LLC now owns 3,642 shares of the company's stock worth $313,000 after purchasing an additional 138 shares in the last quarter. Xponance Inc. lifted its position in shares of Novo Nordisk A/S by 4.9% in the fourth quarter. Xponance Inc. now owns 3,156 shares of the company's stock valued at $271,000 after acquiring an additional 146 shares in the last quarter. 180 Wealth Advisors LLC lifted its position in shares of Novo Nordisk A/S by 3.6% in the first quarter. 180 Wealth Advisors LLC now owns 5,014 shares of the company's stock valued at $348,000 after acquiring an additional 173 shares in the last quarter. LRI Investments LLC increased its stake in Novo Nordisk A/S by 1.4% in the fourth quarter. LRI Investments LLC now owns 13,060 shares of the company's stock valued at $1,123,000 after purchasing an additional 176 shares during the last quarter. Finally, Beacon Financial Group increased its stake in Novo Nordisk A/S by 6.5% in the first quarter. Beacon Financial Group now owns 2,884 shares of the company's stock valued at $200,000 after purchasing an additional 177 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Up 1.0%

Shares of NVO opened at $64.96 on Tuesday. The firm's fifty day moving average is $70.34 and its two-hundred day moving average is $74.21. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $139.74. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70. The stock has a market cap of $290.05 billion, a PE ratio of 19.22, a price-to-earnings-growth ratio of 1.24 and a beta of 0.64.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The firm had revenue of $11.87 billion during the quarter. Research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on NVO shares. Wall Street Zen upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th. Guggenheim cut Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. BNP Paribas assumed coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating for the company. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Finally, BMO Capital Markets restated a "market perform" rating and set a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $112.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.